{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:39:35Z","timestamp":1766407175293,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00774","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T04:34:28Z","timestamp":1565757268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Qiuhua","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Men","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suodi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/SPC.0b013e32835689cd","article-title":"Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study","volume":"6","author":"Coleman","year":"2012","journal-title":"Curr Opin Support Palliat Care."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Curr Pharm Des."},{"key":"B3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"C19","DOI":"10.1016\/0303-7207(91)90222-E","article-title":"Is prolonged stimulation of bone growth a therapeutic possibility?","volume":"75","author":"Mundy","year":"1991","journal-title":"Mol Cell Endocrinol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer."},{"key":"B6","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3747\/co.19.1011","article-title":"Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art","volume":"19","author":"Clemons","year":"2012","journal-title":"Curr Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients\u2014experience from a single cancer centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD003474","DOI":"10.1002\/14651858.CD003474.pub4","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International bone and cancer study group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol."},{"key":"B11","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma,. V22016"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guidelineupdate on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement","volume":"82","author":"Durie","year":"2007","journal-title":"Mayo Clin Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/154405910708601102","article-title":"Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates","volume":"86","author":"Kimmel","year":"2007","journal-title":"J Dent Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-014-2906-x","article-title":"A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events","volume":"144","author":"Addison","year":"2014","journal-title":"Breast Cancer Res Treat."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1093\/annonc\/mdv284","article-title":"Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis","volume":"26","author":"Ibrahim","year":"2015","journal-title":"Ann Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/SPC.0000000000000084","article-title":"Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits","volume":"8","author":"Jacobs","year":"2014","journal-title":"Curr Opin Support Palliat Care."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2146\/ajhp140041","article-title":"Effects of maternal bisphosphonate use on fetal and neonatal outcomes","volume":"71","author":"Green","year":"2014","journal-title":"Am J Health Syst Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/2193-1801-3-577","article-title":"Effects of de-escalated bisphophonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases","volume":"3","author":"Addison","year":"2014","journal-title":"Springerplus."},{"key":"B22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/COC.0b013e3182568f7a","article-title":"Randomized feasibility study of de-escalated (every 12 wk) veresus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer","volume":"36","author":"Amir","year":"2013","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA."},{"key":"B24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/jco.2012.30.15_suppl.511","article-title":"Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer","volume":"30","author":"Coleman","year":"2012","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jbo.2013.07.004","article-title":"Effects of de-escalated bisphosphonate therapy on the functional assessment of cancer therapy-bone pain, brief pain inventory and bone biomarkers","volume":"24","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol."},{"key":"B27","unstructured":"ClinicalTrials.gov2010"},{"key":"B28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(04)01596-7","article-title":"Assessment of therapeutic response in patients with metastatic bone disease","volume":"5","author":"Clamp","year":"2004","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-014-3015-6","article-title":"Randomised, phase II, placebocontrolled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study","volume":"146","author":"Clemons","year":"2014","journal-title":"Breast Cancer Res Treat."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","article-title":"Bone resorption predicts for skeletal complications in metastatic bone disease","volume":"89","author":"Brown","year":"2003","journal-title":"Br J Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jbo.2013.03.001","article-title":"De-escalated administration of bonetargeted agents in patients with breast and prostate cancer-a survey of Canadian oncologists","volume":"2","author":"Hutton","year":"2013","journal-title":"J Bone Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jbo.2013.05.002","article-title":"Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: a patient survey","volume":"2","author":"Hutton","year":"2013","journal-title":"J Bone Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.3747\/co.19.1009","article-title":"Time to put an end to the \u2018one size fits all' approach to bisphosphonate use in patients with metastatic breast cancer?","volume":"19","author":"Kuchuk","year":"2012","journal-title":"Curr Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.coms.2015.06.005","article-title":"Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw","volume":"27","author":"Fung","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur J Cancer."},{"key":"B39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.22203\/eCM.v030a19","article-title":"The effect of bisphosphonate treatment on the biochemical and cellular events during bone remodelling in response to microinjury stimulation","volume":"30","author":"Mulcahy","year":"2015","journal-title":"Eur Cell Mater."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T17:38:35Z","timestamp":1610818715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":39,"alternative-id":["10.3389\/fonc.2019.00774"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00774","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"article-number":"774"}}